Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCd induction/consolidation followed by pomalidomide with or without dexamethasone maintenance in first relapse multiple myeloma
NL-OMON53109Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Aug 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pomalidomide, carfilzomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by HOVON. Primary endpoints: Progression-free survival from randomization and Response rate after induction and consolidation. Started Aug 2015; status: recruiting.
02
Drugs
pomalidomidecarfilzomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON53109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53109.